Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
| Autor: | Sarah Isabelle Huwer, Lisa Jung, I Juhasz-Böss, Gilda Schmidt, Erich-Franz Solomayer, Stephanie Juhasz-Böss, Carolin Müller |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Logistic regression Disease-Free Survival 03 medical and health sciences Young Adult 0302 clinical medicine Breast cancer Clinical trials Internal medicine Antineoplastic Combined Chemotherapy Protocols Pathologic complete response Medicine Humans 030212 general & internal medicine Complete response Aged Chemotherapy Tumor biology business.industry Neo-adjuvant therapy Medical record Obstetrics and Gynecology General Medicine Middle Aged Gynecologic Oncology medicine.disease Neoadjuvant Therapy Discontinuation Clinical trial Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Neoplasm Recurrence Local business |
| Zdroj: | Archives of Gynecology and Obstetrics |
| ISSN: | 1432-0711 |
| Popis: | Purpose Pathologic complete response is associated with longer disease-free survival and better overall survival after neoadjuvant chemotherapy in breast cancer patients. We, therefore, evaluated factors influencing pathologic complete response. Methods Patients receiving neoadjuvant chemotherapy from 2015 to 2018 at the Saarland University Hospital were included. Patients’ age, tumor stage, tumor biology, genetic mutation, recurrent cancer, discontinuation of chemotherapy, and participation in clinical trials were extracted from electronic medical records. Binary logistic regression was performed to evaluate the influence of these factors on pathologic complete response. Results Data of 183 patients were included. The median patient’s age was 54 years (22–78). The median interval between diagnosis and onset of chemotherapy was 28 days (14–91); between end of chemotherapy and surgery 28 days (9–57). Sixty-two patients (34%) participated in clinical trials for chemotherapy. A total of 86 patients (47%) achieved pathologic complete response. Patient’s age, genetic mutation, recurrent cancers, or discontinuation of chemotherapy (due to side effects) and time intervals (between diagnosis and onset of chemotherapy, as well as between end of chemotherapy and surgery) did not influence pathologic complete response. Patients with high Ki67, high grading, Her2 positive tumors, as well as patients participating in clinical trials for chemotherapy had a higher chance of having pathologic complete response. Patients with Luminal B tumors had a lower chance for pathologic complete response. Conclusion Particularly patients with high risk cancer and patients, participating in clinical trials benefit most from chemotherapy. Therefore, breast cancer patients can be encouraged to participate in clinical trials for chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink